Effect of telomerase inhibitors on malignant breast cancer cells
Current therapies have nominal effect on the most intrusive-type of breast cancers (triple-negative) that have a higher tendency to metastasize or recur. Recent studies reveal an enzyme, telomerase, as key for unlimited cell growth (immortality) and replication. Therefore, our objectives were to assess (i) short- and (ii) long-term effects of a novel anti-telomerase agent (GV6) developed at our institute and compare it to a known analogue, BIBR1532 on MDA-MB 231 breast cancer cells. Cell viability was measured on days 5, 9, 14, 18 and 27 after treatment with GV6 (n=4), BIBR1532 (n=4) or solvent alone (Control, n=3). The number of viable cells in GV6 and BIBR1532 treated flasks (T75) fell about 35% (p<.05) and 40% (p<.05) relative to Control by day 14, respectively. Further drops of roughly 35% (p<.05) were observed for both on day 27. Our results indicate the anti-telomerase effects of GV6 parallel that of BIBR1532 and should be investigated further.
Faculty Mentor: Osman Patel, Cell and Molecular Biology
Page last modified August 2, 2013